ABIVAX Société Anonyme (NASDAQ:ABVX) Shares Gap Down – What’s Next?

ABIVAX Société Anonyme (NASDAQ:ABVX) shares gapped down before the market opened on Thursday . The stock had previously closed at $10.18, but opened at $9.78. ABIVAX Société Anonyme shares last traded at $9.70, with a volume of 911 shares changing hands.

Wall Street Analyst Weigh In

Separately, Laidlaw began coverage on shares of ABIVAX Société Anonyme in a report on Monday, July 29th. They set a “buy” rating and a $48.00 price objective for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, ABIVAX Société Anonyme presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.50.

ABIVAX Société Anonyme Trading Down 1.2 %

The business’s fifty day moving average is $10.69 and its two-hundred day moving average is $12.20.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Several large investors have recently modified their holdings of the business. Janus Henderson Group PLC lifted its position in shares of ABIVAX Société Anonyme by 18.2% in the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock worth $12,113,000 after purchasing an additional 131,414 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of ABIVAX Société Anonyme in the 1st quarter worth approximately $81,000. abrdn plc lifted its position in shares of ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after purchasing an additional 198,225 shares during the period. Kennedy Capital Management LLC lifted its position in shares of ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after purchasing an additional 31,331 shares during the period. Finally, Walleye Capital LLC lifted its position in shares of ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after purchasing an additional 80,807 shares during the period. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.